JP2008538173A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008538173A5 JP2008538173A5 JP2007553353A JP2007553353A JP2008538173A5 JP 2008538173 A5 JP2008538173 A5 JP 2008538173A5 JP 2007553353 A JP2007553353 A JP 2007553353A JP 2007553353 A JP2007553353 A JP 2007553353A JP 2008538173 A5 JP2008538173 A5 JP 2008538173A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- luca2
- tumor
- antibody
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000962526 Homo sapiens Hyaluronidase-2 Proteins 0.000 claims 35
- 102100039285 Hyaluronidase-2 Human genes 0.000 claims 35
- 210000004027 cell Anatomy 0.000 claims 35
- 206010028980 Neoplasm Diseases 0.000 claims 28
- 201000011510 cancer Diseases 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 17
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 206010024612 Lipoma Diseases 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 208000003174 Brain Neoplasms Diseases 0.000 claims 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims 8
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 8
- 206010039491 Sarcoma Diseases 0.000 claims 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 8
- 201000010881 cervical cancer Diseases 0.000 claims 8
- 208000037819 metastatic cancer Diseases 0.000 claims 8
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 8
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 8
- 208000005243 Chondrosarcoma Diseases 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 7
- 201000001441 melanoma Diseases 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 239000003446 ligand Substances 0.000 claims 6
- 208000008732 thymoma Diseases 0.000 claims 6
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 208000014951 hematologic disease Diseases 0.000 claims 5
- 230000003993 interaction Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 208000030507 AIDS Diseases 0.000 claims 4
- 208000001783 Adamantinoma Diseases 0.000 claims 4
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims 4
- 208000008884 Aneurysmal Bone Cysts Diseases 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 4
- 206010005949 Bone cancer Diseases 0.000 claims 4
- 208000018084 Bone neoplasm Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000001843 Carotid Body Tumor Diseases 0.000 claims 4
- 208000037211 Carotid body tumour Diseases 0.000 claims 4
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 4
- 206010014967 Ependymoma Diseases 0.000 claims 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 4
- 208000021309 Germ cell tumor Diseases 0.000 claims 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000000172 Medulloblastoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 4
- 206010029260 Neuroblastoma Diseases 0.000 claims 4
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 4
- 206010033963 Parathyroid tumour Diseases 0.000 claims 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 206010038389 Renal cancer Diseases 0.000 claims 4
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 4
- 206010057644 Testis cancer Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 208000008383 Wilms tumor Diseases 0.000 claims 4
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 4
- 230000000890 antigenic effect Effects 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 210000001185 bone marrow Anatomy 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 4
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 201000011523 endocrine gland cancer Diseases 0.000 claims 4
- 201000010175 gallbladder cancer Diseases 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 208000006359 hepatoblastoma Diseases 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 208000022013 kidney Wilms tumor Diseases 0.000 claims 4
- 201000010982 kidney cancer Diseases 0.000 claims 4
- 201000010260 leiomyoma Diseases 0.000 claims 4
- 206010024627 liposarcoma Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000030883 malignant astrocytoma Diseases 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 206010027191 meningioma Diseases 0.000 claims 4
- 201000008026 nephroblastoma Diseases 0.000 claims 4
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims 4
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 4
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 4
- 201000008968 osteosarcoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims 4
- 208000028591 pheochromocytoma Diseases 0.000 claims 4
- 208000010916 pituitary tumor Diseases 0.000 claims 4
- 201000011096 spinal cancer Diseases 0.000 claims 4
- 208000014618 spinal cord cancer Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 206010042863 synovial sarcoma Diseases 0.000 claims 4
- 201000003120 testicular cancer Diseases 0.000 claims 4
- 210000001685 thyroid gland Anatomy 0.000 claims 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 4
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 3
- 208000000035 Osteochondroma Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 230000003352 fibrogenic effect Effects 0.000 claims 3
- 201000010103 fibrous dysplasia Diseases 0.000 claims 3
- 201000002529 islet cell tumor Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims 3
- 210000004976 peripheral blood cell Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 3
- 206010004593 Bile duct cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 2
- 206010068116 Metastatic uterine cancer Diseases 0.000 claims 2
- 201000009365 Thymic carcinoma Diseases 0.000 claims 2
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 201000007487 gallbladder carcinoma Diseases 0.000 claims 2
- 201000008822 gestational choriocarcinoma Diseases 0.000 claims 2
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 1
- 208000013558 Developmental Bone disease Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000003651 basophil Anatomy 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000009500 myxoid chondrosarcoma Diseases 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 230000003094 perturbing effect Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000006402 rhabdoid cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64900705P | 2005-01-31 | 2005-01-31 | |
| PCT/US2006/003382 WO2006083852A2 (en) | 2005-01-31 | 2006-01-31 | Luca2 and antibodies that bind thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008538173A JP2008538173A (ja) | 2008-10-16 |
| JP2008538173A5 true JP2008538173A5 (enExample) | 2009-03-05 |
Family
ID=36777832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007553353A Pending JP2008538173A (ja) | 2005-01-31 | 2006-01-31 | Ｌｕｃａ２およびそれに結合する抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7847070B2 (enExample) |
| EP (1) | EP1846032A4 (enExample) |
| JP (1) | JP2008538173A (enExample) |
| CA (1) | CA2596115A1 (enExample) |
| WO (1) | WO2006083852A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3045475B1 (en) | 2008-04-02 | 2017-10-04 | MacroGenics, Inc. | Bcr-complex-specific antibodies and methods of using same |
| US8241861B1 (en) | 2008-07-08 | 2012-08-14 | Insilicos, Llc | Methods and compositions for diagnosis or prognosis of cardiovascular disease |
| SG10201407908VA (en) | 2008-12-19 | 2015-01-29 | Macrogenics Inc | Covalent diabodies and uses thereof |
| JP5757626B2 (ja) * | 2009-09-04 | 2015-07-29 | 国立大学法人東北大学 | ヒトにおける新たな腎疾患マーカー物質 |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| NZ705128A (en) | 2010-03-04 | 2015-04-24 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| JP5964300B2 (ja) | 2010-08-02 | 2016-08-03 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディおよびその使用 |
| BR112013029892A2 (pt) | 2011-05-21 | 2016-12-20 | Macrogenics Inc | polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| TN2016000525A1 (en) | 2014-05-29 | 2018-04-04 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| SG10202010506TA (en) | 2015-07-30 | 2020-11-27 | Macrogenics Inc | Pd-1-binding molecules and methods of use thereof |
| US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| CA3020864A1 (en) | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
| BR112019017628A2 (pt) | 2017-02-24 | 2020-07-07 | Macrogenics, Inc. | molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição |
| US11795226B2 (en) | 2017-12-12 | 2023-10-24 | Macrogenics, Inc. | Bispecific CD16-binding molecules and their use in the treatment of disease |
| EP3752196A4 (en) | 2018-02-15 | 2022-03-23 | MacroGenics, Inc. | CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US43029A (en) * | 1864-06-07 | Improvement in explosive projectiles for ordnance | ||
| US16006A (en) * | 1856-11-04 | Kocking-chaik | ||
| US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
| US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
| JPS5726506B2 (enExample) | 1974-03-08 | 1982-06-04 | ||
| US4105603A (en) | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| USRE30548E (en) | 1979-08-31 | 1981-03-17 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5753229A (en) * | 1991-09-25 | 1998-05-19 | Mordoh; Jose | Monoclonal antibodies reactive with tumor proliferating cells |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| EP1473301A3 (en) | 1997-06-04 | 2005-01-26 | Cornell Research Foundation, Inc. | Betulinol derivatives |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| US20020164715A1 (en) | 2000-07-10 | 2002-11-07 | Lin Ji | Chromosome 3p21.3 genes are tumor suppressors |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7527969B2 (en) | 2002-06-19 | 2009-05-05 | Raven Biotechnologies, Inc. | RAAG10 cell surface target and a family of antibodies recognizing that target |
| US6682904B1 (en) * | 2002-08-15 | 2004-01-27 | Deliatroph Pharmaceuticals, Inc. | Specific inhibitors of hyaluronidase 2, and methods of identifying and using same |
| PL1678194T3 (pl) * | 2003-10-10 | 2014-01-31 | Alchemia Oncology Pty Ltd | Modulowanie syntezy i degradacji hialuronianu w leczeniu choroby |
| JP2006014694A (ja) * | 2004-07-05 | 2006-01-19 | Mitsubishi Kagaku Iatron Inc | ペプチド、その抗体及びその抗体の製法 |
-
2006
- 2006-01-31 WO PCT/US2006/003382 patent/WO2006083852A2/en not_active Ceased
- 2006-01-31 JP JP2007553353A patent/JP2008538173A/ja active Pending
- 2006-01-31 US US11/344,814 patent/US7847070B2/en not_active Expired - Fee Related
- 2006-01-31 CA CA002596115A patent/CA2596115A1/en not_active Abandoned
- 2006-01-31 EP EP06719967A patent/EP1846032A4/en not_active Withdrawn
-
2010
- 2010-10-29 US US12/915,842 patent/US20110045006A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010508847A5 (enExample) | ||
| JP2008538173A5 (enExample) | ||
| JP2008532488A5 (enExample) | ||
| JP2008529494A5 (enExample) | ||
| JP2005532050A5 (enExample) | ||
| US12453780B2 (en) | Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use | |
| JP7682789B2 (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| CN113896792B (zh) | 间皮素结合蛋白质 | |
| CN110913908B (zh) | 靶向msln的三特异性蛋白质及使用方法 | |
| JP2010110329A5 (enExample) | ||
| AU2025201864A1 (en) | Anti-cd24 compositions and uses thereof | |
| JP2020103301A5 (enExample) | ||
| CN111183156A (zh) | 用于用抗cd19/cd20免疫治疗来治疗癌症的组合物和方法 | |
| JP2013529059A5 (enExample) | ||
| JP2008508858A5 (enExample) | ||
| JP2007532139A5 (enExample) | ||
| JP2010510809A5 (enExample) | ||
| JP2008526256A5 (enExample) | ||
| JP2005538701A5 (enExample) | ||
| JP2006507013A5 (enExample) | ||
| JP2012503203A5 (enExample) | ||
| TW202146456A (zh) | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 | |
| JP2009297037A5 (enExample) | ||
| JP2008516970A5 (enExample) | ||
| JP2007536932A5 (enExample) |